Organogenesis (NASDAQ:ORGO) Shares Gap Down – Time to Sell?

Organogenesis (NASDAQ:ORGO) shares gapped down before the market opened on Friday . The stock had previously closed at $5.87, but opened at $5.70. Organogenesis shares last traded at $5.4130, with a volume of 202,067 shares traded.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ORGO. BTIG Research reiterated a “buy” rating and issued a $9.00 price target on shares of Organogenesis in a research report on Friday. Weiss Ratings reiterated a “sell (d+)” rating on shares of Organogenesis in a report on Monday. Finally, Wall Street Zen raised shares of Organogenesis from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Organogenesis presently has a consensus rating of “Hold” and a consensus target price of $8.00.

Organogenesis Stock Performance

The stock’s 50 day moving average is $5.03 and its two-hundred day moving average is $4.59. The stock has a market capitalization of $684.04 million, a price-to-earnings ratio of -44.92 and a beta of 1.47. The company has a current ratio of 3.32, a quick ratio of 2.88 and a debt-to-equity ratio of 0.01.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $0.11. The company had revenue of $150.86 million for the quarter, compared to analyst estimates of $134.10 million. Organogenesis had a positive return on equity of 4.01% and a negative net margin of 1.30%. Analysts expect that Organogenesis will post -0.07 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Glenn H. Nussdorf sold 200,000 shares of the business’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $5.14, for a total value of $1,028,000.00. Following the sale, the director owned 2,565,591 shares of the company’s stock, valued at $13,187,137.74. The trade was a 7.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold 500,000 shares of company stock valued at $2,620,120 in the last 90 days. 33.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Assenagon Asset Management S.A. increased its holdings in shares of Organogenesis by 69.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 4,854,942 shares of the company’s stock worth $20,488,000 after acquiring an additional 1,997,038 shares during the last quarter. Trexquant Investment LP bought a new position in Organogenesis during the 1st quarter worth $516,000. Vanguard Group Inc. lifted its holdings in shares of Organogenesis by 23.4% during the first quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company’s stock worth $19,144,000 after buying an additional 841,618 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Organogenesis by 32.7% in the first quarter. American Century Companies Inc. now owns 131,220 shares of the company’s stock valued at $567,000 after acquiring an additional 32,328 shares during the period. Finally, Acadian Asset Management LLC grew its stake in shares of Organogenesis by 3.9% in the second quarter. Acadian Asset Management LLC now owns 2,424,363 shares of the company’s stock valued at $8,862,000 after acquiring an additional 91,118 shares in the last quarter. 49.57% of the stock is currently owned by institutional investors and hedge funds.

Organogenesis Company Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.